Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ARRY-543: Phase I data

In an open-label, dose-escalation Phase I trial in patients with refractory

Read the full 118 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE